CoChat

Pancreatic Cancer Microenvironment and Cellular Composition: Current Understandings and Therapeutic Approaches

Open access
Truong, Linh-Huyen, Pauklin, Siim · 2021 · Cancers

The DOI matches its Crossref record; 158 of the 159 references it cites were found in a registry or an index.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal human solid tumors, despite great efforts in improving therapeutics over the past few decades. In PDAC, the distinct characteristic of the tumor microenvironment (TME) is the main barrier for developing effective treatments. PDAC TME is characterized by a dense stroma, cancer-associated fibroblasts, and immune cells populations that crosstalk to the subpopulations of neoplastic cells that include cancer stem cells (CSCs). The heterogeneity in TME is also exhibited in the diversity and dynamics of acellular components, including the Extracellular matrix (ECM), cytokines, growth factors, and secreted ligands to signaling pathways. These contribute to drug resistance, metastasis, and relapse in PDAC. However, clinical trials targeting TME components have often reported unexpected results and still have not benefited patients. The failures in those trials and various efforts to understand the PDAC biology demonstrate the highly heterogeneous and multi-faceted TME compositions and the complexity of their interplay within TME. Hence, further functional and mechanistic insight is needed. In this review, we will present a current understanding of PDAC biology with a focus on the heterogeneity in TME and crosstalk among its components. We also discuss clinical challenges and the arising therapeutic opportunities in PDAC research.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers13195028

Cites

158 of 158 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 PDAC microenvironment and the cellular interplay. Pancreatic ductal adenocarcinoma (PDAC) is highly heterogeneous in both cellular and acellular components. The tumor cells themselves are varied in mutation/gene expression profile, which manipulates the surrounding fibroblasts and immune cells. In turn, the tumor microenvironment components interact with each other and with tumor cells in a pro-tumor support fashion. The major interplay in PDAC includes (i) CAFs activation which leads to creating a desmoplastic stroma, (ii) metabolic reprogramming, (iii) immunological transformation, and (iv) metastasis initiating events in early stages of tumor development. Treg = regulatory T cell, Teff = effector T cell, PaSC = Pancreatic stellate cells, PDAC = pancreatic ductal adenocarcinoma, EMC = extracellular matrix, myCAF = myofibroplastic cancer associated fibroblast, iCAF = inflammatory cancer associated fibroblast. Figure made in BioRender.
Figure 1 PDAC microenvironment and the cellular interplay. Pancreatic ductal adenocarcinoma (PDAC) is highly heterogeneous in both cellular and acellular components. The tumor cells themselves are varied in mutation/gene expression profile, which manipulates the surrounding fibroblasts and immune cells. In turn, the tumor microenvironment components interact with each other and with tumor cells in a pro-tumor support fashion. The major interplay in PDAC includes (i) CAFs activation which leads to creating a desmoplastic stroma, (ii) metabolic reprogramming, (iii) immunological transformation, and (iv) metastasis initiating events in early stages of tumor development. Treg = regulatory T cell, Teff = effector T cell, PaSC = Pancreatic stellate cells, PDAC = pancreatic ductal adenocarcinoma, EMC = extracellular matrix, myCAF = myofibroplastic cancer associated fibroblast, iCAF = inflammatory cancer associated fibroblast. Figure made in BioRender.CC BY · PubMed Central
Figure 2 Neoplastic cells and ECM targeting approaches in PDAC treatment. Because of its large contribution to tumor development and treatment resistance, the heterogeneity of tumor cells, mutations, and ECM of PDAC are also attractive targets for therapeutic development. Targeting the KRAS protein and its upstream and downstream signaling are some of the most potential targets for drug development and are under investigation in several trials. Besides that, the therapeutic approaches for eliminating cancer stem cells in PDAC focus on targeting particular major signaling pathways by small molecules or targeting core genetic regulators, such as microRNA, as listed in the boxes. The ECM consists of collagens, fibronectin, and other proteins that can be targeted, together with other therapeutic strategies. PaSC = pancreatic stellate cells, PDAC = pancreatic ductal adenocarcinoma, EMC = extracellular matrix, myCAF = myofibroplastic cancer associated fibroblast, iCAF = inflammatory cancer associated fibroblast. Figure made in BioRender.
Figure 2 Neoplastic cells and ECM targeting approaches in PDAC treatment. Because of its large contribution to tumor development and treatment resistance, the heterogeneity of tumor cells, mutations, and ECM of PDAC are also attractive targets for therapeutic development. Targeting the KRAS protein and its upstream and downstream signaling are some of the most potential targets for drug development and are under investigation in several trials. Besides that, the therapeutic approaches for eliminating cancer stem cells in PDAC focus on targeting particular major signaling pathways by small molecules or targeting core genetic regulators, such as microRNA, as listed in the boxes. The ECM consists of collagens, fibronectin, and other proteins that can be targeted, together with other therapeutic strategies. PaSC = pancreatic stellate cells, PDAC = pancreatic ductal adenocarcinoma, EMC = extracellular matrix, myCAF = myofibroplastic cancer associated fibroblast, iCAF = inflammatory cancer associated fibroblast. Figure made in BioRender.CC BY · PubMed Central
Figure 3 Immunotherapies to treat PDAC. There are several proposed strategies to target immunological aspects of PDAC which are (i) cancer vaccines, (ii) targeting immunosuppressive mechanism by immune checkpoint blockage therapy, and (iii) adoptive cell transfer which are comprised of NK, Cytotoxic lymphocyte, and CAR-T therapies. PDAC = pancreatic ductal adenocarcinoma, PD-1 = programmed cell death protein 1, CTLA-4 = cytotoxic T lymphocyte associated protein 4, TCR = T cell receptor, Treg = regulatory T cell, MDSC = myeloid derived suppressor cell, M2 = Tumor associated M2 macrophage, N2 = tumor associated N1 neutrophil, MHC = major histocompatibility complex, CAR = chimeric antigen receptor. Figure made in BioRender.
Figure 3 Immunotherapies to treat PDAC. There are several proposed strategies to target immunological aspects of PDAC which are (i) cancer vaccines, (ii) targeting immunosuppressive mechanism by immune checkpoint blockage therapy, and (iii) adoptive cell transfer which are comprised of NK, Cytotoxic lymphocyte, and CAR-T therapies. PDAC = pancreatic ductal adenocarcinoma, PD-1 = programmed cell death protein 1, CTLA-4 = cytotoxic T lymphocyte associated protein 4, TCR = T cell receptor, Treg = regulatory T cell, MDSC = myeloid derived suppressor cell, M2 = Tumor associated M2 macrophage, N2 = tumor associated N1 neutrophil, MHC = major histocompatibility complex, CAR = chimeric antigen receptor. Figure made in BioRender.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 158 references

Cited by

See all 115

Metadata

Authors
Truong, L.-H., & Pauklin, S.
Affiliations
University of Oxford (GB)
Corresponding author
Pauklin, Siim
Venue
Cancers
Publisher
MDPI AG
Published
2021-10-08
Volume
13
Issue
19
Pages
5028
ISSN
2072-6694 (ISSN-L)
OpenAlex
W3201923441
Cited by
102
References
159
Citations by year
2026: 23 · 2025: 23 · 2024: 26 · 2023: 14 · 2022: 15 · 2021: 1
FWCI
1.88
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Cancer Research UK (C59392/A25064)
  • Vingroup (Vingroup Science and Technology Scholarship Program for Overseas study)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
Keywords
pancreatic ductal adenocarcinoma, tumor microenvironment, tumor stroma, cancer-associated fibroblasts, extracellular matrix, cancer stem cells, immune cells, drug resistance, metastasis, TME-targeted therapy, cytokines and growth factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pancreatic Cancer Microenvironment and Cellular Composition: Current Understandings and Therapeutic Approaches. https://app.cochat.ai/papers/10.3390/cancers13195028
The paper
Truong, L.-H., & Pauklin, S. (2021). Pancreatic Cancer Microenvironment and Cellular Composition: Current Understandings and Therapeutic Approaches. Cancers. https://doi.org/10.3390/cancers13195028

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.